Cardiol Therapeutics (CRDL) Net Income towards Common Stockholders (2020 - 2026)
Cardiol Therapeutics (CRDL) posted Net Income towards Common Stockholders of -$6.9 million for Q1 2026, up 6.29% on a QoQ basis from -$7.4 million in Q3 2025, and down 21.58% year-over-year from -$8.8 million in Q1 2025.
Cardiol Therapeutics (CRDL) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Cardiol Therapeutics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$6.9 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 21.58% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.4 million (up 6.05% YoY) and the FY2025 annual result came in at -$24.1 million, up 13.91% from the prior year.
- Net Income towards Common Stockholders was -$6.9 million for Q1 2026 at Cardiol Therapeutics, up from -$7.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$4.7 million in Q2 2023 and bottomed at -$10.4 million in Q3 2024.
- A 5-year average of -$6.9 million and a median of -$6.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 43.66% — and 2024, when it slumped 81.51%.
- Cardiol Therapeutics' Net Income towards Common Stockholders stood at -$6.4 million in 2022, then gained by 10.51% to -$5.7 million in 2023, then slumped by 81.51% to -$10.4 million in 2024, then gained by 28.64% to -$7.4 million in 2025, then increased by 6.29% to -$6.9 million in 2026.
- Business Quant data shows CRDL's Net Income towards Common Stockholders at -$6.9 million in Q1 2026, -$7.4 million in Q3 2025, and -$6.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.01 Bn | 87.15 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.35 Bn | 18.55 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.73 Bn | 16.41 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.56 Bn | 12.14 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Cardiol Therapeutics | 128.61 Mn | 128.61 Mn | - | -6.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.93 Mn |
| Sep 30, 2025 | -7.40 Mn |
| Jun 30, 2025 | -6.08 Mn |
| Mar 31, 2025 | -5.70 Mn |
| Sep 30, 2024 | -10.37 Mn |
| Jun 30, 2024 | -5.66 Mn |
| Mar 31, 2024 | -6.24 Mn |
| Sep 30, 2023 | -5.71 Mn |
| Jun 30, 2023 | -4.70 Mn |
| Mar 31, 2023 | -5.76 Mn |
| Dec 31, 2022 | -6.38 Mn |
| Sep 30, 2022 | -10.14 Mn |
| Jun 30, 2022 | -7.24 Mn |
| Mar 31, 2022 | -7.73 Mn |
| Dec 31, 2021 | -10.57 Mn |
| Sep 30, 2021 | -8.05 Mn |
| Jun 30, 2021 | -5.20 Mn |
| Mar 31, 2021 | -7.08 Mn |
| Dec 31, 2020 | -7.36 Mn |
| Jun 30, 2020 | -2.57 Mn |